Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.

Bonsignori M, Wiehe K, Grimm SK, Lynch R, Yang G, Kozink DM, Perrin F, Cooper AJ, Hwang KK, Chen X, Liu M, McKee K, Parks RJ, Eudailey J, Wang M, Clowse M, Criscione-Schreiber LG, Moody MA, Ackerman ME, Boyd SD, Gao F, Kelsoe G, Verkoczy L, Tomaras GD, Liao HX, Kepler TB, Montefiori DC, Mascola JR, Haynes BF.

J Clin Invest. 2014 Apr;124(4):1835-43. doi: 10.1172/JCI73441. Epub 2014 Mar 10.

2.

9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.

Kobie JJ, Alcena DC, Zheng B, Bryk P, Mattiacio JL, Brewer M, Labranche C, Young FM, Dewhurst S, Montefiori DC, Rosenberg AF, Feng C, Jin X, Keefer MC, Sanz I.

PLoS One. 2012;7(4):e35356. doi: 10.1371/journal.pone.0035356. Epub 2012 Apr 18.

3.

Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design?

Bonsignori M.

Expert Rev Vaccines. 2014 Nov;13(11):1271-3. doi: 10.1586/14760584.2014.938056. Epub 2014 Jul 12.

4.

High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.

Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, Feng Y, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

Sci Transl Med. 2012 Jul 11;4(142):142ra96. doi: 10.1126/scitranslmed.3003752.

5.

Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M; NISC Comparative Sequencing Program, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR.

Science. 2011 Sep 16;333(6049):1593-602. doi: 10.1126/science.1207532. Epub 2011 Aug 11.

6.

Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.

Sather DN, Carbonetti S, Malherbe DC, Pissani F, Stuart AB, Hessell AJ, Gray MD, Mikell I, Kalams SA, Haigwood NL, Stamatatos L.

J Virol. 2014 Nov;88(22):12968-81. doi: 10.1128/JVI.01816-14. Epub 2014 Aug 13.

7.

Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.

Ingale J, Tran K, Kong L, Dey B, McKee K, Schief W, Kwong PD, Mascola JR, Wyatt RT.

J Virol. 2014 Dec;88(24):14002-16. doi: 10.1128/JVI.02614-14. Epub 2014 Sep 24. Erratum in: J Virol. 2015 Jun;89(12):6526.

8.

Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization.

Willis JR, Finn JA, Briney B, Sapparapu G, Singh V, King H, LaBranche CC, Montefiori DC, Meiler J, Crowe JE Jr.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4446-51. doi: 10.1073/pnas.1518405113. Epub 2016 Apr 4.

9.

Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Sajadi MM, Lewis GK, Seaman MS, Guan Y, Redfield RR, DeVico AL.

J Virol. 2012 May;86(9):5014-25. doi: 10.1128/JVI.06547-11. Epub 2012 Feb 29.

10.

Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.

Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR.

J Virol. 2012 May;86(10):5844-56. doi: 10.1128/JVI.07139-11. Epub 2012 Mar 14.

11.
12.

Study of antibody repertoires to the CD4 binding site of gp120 of a Chinese HIV-1-infected elite neutralizer, using 454 sequencing and single-cell sorting.

Li D, Wang Z, Ren L, Zhang J, Feng G, Hong K, Hao Y, Qi Z, Liang H, Shao Y.

Arch Virol. 2016 Apr;161(4):789-99. doi: 10.1007/s00705-015-2710-x. Epub 2015 Dec 15.

PMID:
26671829
13.

9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles.

Alcéna DC, Kobie JJ, Kaminski DA, Rosenberg AF, Mattiacio JL, Brewer M, Dewhurst S, Dykes C, Jin X, Keefer MC, Sanz I.

PLoS One. 2013 Dec 26;8(12):e85098. doi: 10.1371/journal.pone.0085098. eCollection 2013.

14.

Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design.

Bonsignori M, Montefiori DC, Wu X, Chen X, Hwang KK, Tsao CY, Kozink DM, Parks RJ, Tomaras GD, Crump JA, Kapiga SH, Sam NE, Kwong PD, Kepler TB, Liao HX, Mascola JR, Haynes BF.

J Virol. 2012 Apr;86(8):4688-92. doi: 10.1128/JVI.07163-11. Epub 2012 Feb 1.

15.

Mouse marginal zone B cells harbor specificities similar to human broadly neutralizing HIV antibodies.

Pujanauski LM, Janoff EN, McCarter MD, Pelanda R, Torres RM.

Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1422-7. doi: 10.1073/pnas.1213713110. Epub 2013 Jan 3.

16.

Reconstitution and characterization of antibody repertoires of HIV-1-infected "elite neutralizers".

Sun Z, Li J, Hu X, Shao Y, Zhang MY.

Antiviral Res. 2015 Jun;118:1-9. doi: 10.1016/j.antiviral.2015.02.006. Epub 2015 Mar 12.

PMID:
25770672
17.

Polyreactivity and autoreactivity among HIV-1 antibodies.

Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rountree W, Bonsignori M, Alam SM, Gao J, Haynes BF, Kelsoe G.

J Virol. 2015 Jan;89(1):784-98. doi: 10.1128/JVI.02378-14. Epub 2014 Oct 29.

18.

Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies.

Kepler TB, Liao HX, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, Stewart S, Anasti K, Kelsoe G, Parks R, Lloyd KE, Stolarchuk C, Pritchett J, Solomon E, Friberg E, Morris L, Karim SS, Cohen MS, Walter E, Moody MA, Wu X, Altae-Tran HR, Georgiev IS, Kwong PD, Boyd SD, Fire AZ, Mascola JR, Haynes BF.

Cell Host Microbe. 2014 Sep 10;16(3):304-13. doi: 10.1016/j.chom.2014.08.006.

19.

Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains.

Fera D, Schmidt AG, Haynes BF, Gao F, Liao HX, Kepler TB, Harrison SC.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10275-80. doi: 10.1073/pnas.1409954111. Epub 2014 Jun 30.

20.

Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.

Prabakaran P, Gan J, Wu YQ, Zhang MY, Dimitrov DS, Ji X.

J Mol Biol. 2006 Mar 17;357(1):82-99. Epub 2006 Jan 9.

PMID:
16426633

Supplemental Content

Support Center